CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model

Journal of Gene Medicine

Volumn 14, Issue 2, 2012, Pages 128-137

  Nguyen Hoai, Tam ^a,b   Baldenhofer, Gerd ^a,b   Ahmed, Mona Sayed ^a,b   Pham Duc, Minh ^a,b   Gries, Margarete ^a,b   Lipp, Martin ^b   Dörken, Bernd ^a,b   Pezzutto, Antonio ^a,b   Westermann, Jörg ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

CCL19; Chemokines; DNA vaccination; ELC; Her2 neu

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 3BETA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TUMOR CELL;

ANIMALS; CHEMOKINE CCL19; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; MICE; MICE, INBRED BALB C; NEOPLASMS; PLASMIDS; RECEPTOR, ERBB-2; RECEPTORS, CCR7; TH1 CELLS; VACCINATION; VACCINES, DNA;

EID: 84857179775     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1651     Document Type: Article

References (60)

1. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application and optimization. Ann Rev Immunol 2000; 18: 927-974.
2. Choo AY, Choo DK, Kim JJ, Weiner DB. DNA vaccination in immunotherapy of cancer. Cancer Res 2005; 123: 137-156.
3. Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004; 114: 1241-1244.
4. Rice J, Ottensmeier CH, Stevenson F. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Immunol 2008; 8: 108-120.
5. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-296.
6. Fin OJ. Cancer immunology. N Engl J Med 2008; 358: 2704-2715.
7. Scheerlinck JP. Genetic adjuvants for DNA vaccines. Vaccine 2001; 19: 2647-2656.
8. Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007; 25: 3731-3741.
9. DellÁgnola C, Biragyn A. Clinical utilisation of chemokines to combat cancer: the double-edged sword. Exp Rev Vaccines 2007; 6: 267-283.
10. Coscia M, Biragyn A. Cancer immunotherapy with chemoattractant peptides. Sem Cancer Biol 2004; 14: 209-218.
11. Messi M, Sallusto F. Chemokine receptor expression in effector and memory T cell subsets. In Lymphocyte Tafficking in health and Disease, Badolato R, Sozzani S (eds) Birkhäuser Verlag: Basel, 2006; 55-70.
12. Sozzani S. Dendritic cell trafficking: more than just chemokines. Cytokine Growth Factor Rev 2005; 16: 581-592.
13. Viola A, Contento RL, Molon B. T cells and their partners: the chemokine dating agency. Trends Immunol 2006; 27: 421-427.
14. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008; 9: 970-980.
15. Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008; 8: 362-371.
16. Radstake TR, van der Voort M, ten Brummelhuis M, et al. Increased expression of CCL18, CCL19 and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors. Ann Rheum Dis 2005; 64: 359-367.
17. Friedman RS, Jacobell J, Krummel MF. Surface-bound chemokines capture and prime T cells for synapse formation. Nat Immunol 2006; 7: 1101-1108.
18. Worbs T, Mempe TR, Bölter J, von Andrian UH, Förster R. CCR7 ligands stimulate the intranodal motility of T lymphocytes in vivo. J Exp Med 2007; 3: 489-495.
19. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-6578.
20. Westermann J, Nguyen-Hoai T, Baldenhofer G, et al. CCL19 (ELC) as an adjuvant for DNA vaccination: Induction of a TH1-type T cell response and enhancement of antitumor immunity. Cancer Gene Ther 2007; 14: 523-532.
21. Luther SA, Bidgol A, Hargreaves DC, et al. Differing activities of homeostatic chemokine CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol 2002; 169: 424-433.
22. Nagata Y, Furugen R, Hiasa A, et al. Peptides derived from a wild-type murine proto-oncogenec-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159: 1336-1343.
23. Piechoski MP, Pilon SA, Wei WZ. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods 2002; 259: 33-42.
24. Kiessling R, Wei WZ, Herrmann F, et al. Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 2002; 85: 101-144.
25. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CM. Vaccination for the treatment and prevention of cancer in animal models. Adv Immunol 2006; 90: 175-213.
26. Curigliano G, Spitaleri G, Pietri E, et al. A breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 2006; 17: 750-762.
27. Baxevanis CN, Voutsas I, Gritzapis AD, Perez SA, Papamichail M. Her-2/neu as a target for cancer vaccines. Immunotherapy 2010; 2: 213-226.
28. + tumors that are refractory to targeted therapies. Cancer Res 2008; 68: 7502-7511.
29. Wei WZ, Shi WP, Galy A, et al. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999; 81: 748-754.
30. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542.
31. Westermann J, Nguyen-Hoai T, Mollweide A, et al. Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization. Gene Ther 2004; 11: 1048-1056.
32. Linndencrona JA, Preise S, Kammertöns T, et al. CD4+ T cell-mediated Her-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004; 109: 259-264.
33. Wei H, Wang S, Zhang D, et al. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin Cancer Res 2009; 15: 4612-4621.
34. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-415.
35. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
36. Nanni P, Landuzzi L, Nicoletti G, et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent. J Immunol 2004; 173: 2288-2296.
37. Reilly RT, Machiels J-PH, Emens LA, et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001; 61: 880-883.
38. + T cells in the antitumor immune response. J Exp Med 1998; 12: 2357-2368.
39. + T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 2000; 165: 4246-4253.
40. + memory T cells. Nature 2006; 441: 890-893.
41. Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunol Immunother 2009; 58: 1337-49.
42. Eo SK, Lee S, Kumaraguru U, Rouse BT. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine 2001; 19: 4685-4693.
43. Toka FN, Gierynska M, Rouse BT. Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1. J Virol 2003; 77: 12742-12752.
44. Okada N, Gao J-Q, Sasaki A, et al. Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: implications for chemokine-based cancer immunotherapy. Biochem Biophys Res Commun 2004; 317: 68-76.
45. Hillinger S, Yang SC, Zhu L, et al. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-γ-dependent antitumor responses in a lung cancer model. J Immunol 2003; 171: 6457-6465.
46. Hillinger S, Yang SC, Batra RK, et al. CCL19 reduces tumour burden in a model of advanced lung cancer. Br J Cancer 2006; 94: 1029-1034.
47. Sallusto F, Lanzavecchia A. Understanding dendritic cell and T-Lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000; 177: 134-140.
48. Braun SE, Chen K, Foster RG, et al. The CC chemokine CKb-11/MIP-3b/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 2000; 164: 4025-4031.
49. Beauvillain C, Cunin P, Doni A, et al. CCR7 is involved in the migration of neutrophils to lymph nodes. Blood 2010; 117: 1196-1204.
50. Baekkevold ES, Yamanaka T, Palframan RT, et al. The CCR7 ligand ELC (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J Exp Med 2001; 193: 1105-1112.
51. Ngo VN, Tang HL, Cyster JG. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J Exp Med 1998; 188: 181-191.
52. Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J Immunol 1998; 161: 3092-3102.
53. Lerbe MC, Burwell T, Vieira PL, et al. Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol Cell Biol 2005; 83: 525-535.
54. Yanagawa Y, Onoé K. CCL19 induces rapid dendritic extension of murine dendritic cells. Blood 2002; 100: 1948-56.
55. Yanagawa Y, Onoé K. CCR7 ligands induce rapid endocytosis in mature dendritic cells with concomitant up-regulation of Cdc42 and Rac activities. Blood 2003; 101: 4923-4929.
56. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004; 22: 1136-1151.
57. + T cell repertoire against Her2/neu antigens in neu transgenic mice is of low avidity with anti tumor activity. Eur J Immunol 2004; 34: 752-761.
58. Yasutomo K. The cellular and molecular mechanism of CD4/CD8 lineage commitment. J Med Invest 2002; 49: 1-6.
59. Rolla S, Nicolo C, Malinarich S, et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and her2/neu transgenic BALB/c mice. J Immunol 2006; 177: 7626-7633.
60. Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005; 201: 1591-1602.